March 24, 2009 - The court approved the settlement, entered the orders approving the plan of allocation, the motion for attorneys’ fees and expenses, and dismissed the action with prejudice.
November 13, 2008 - The court preliminarily approved the settlement.

October 23, 2008 - Parties filed a stipulation of settlement.

March 10, 2008 - The court granted the defendants' motion to dismiss without prejudice as to certain defendants in relation to certain claims.

February 15, 2008 - The defendants filed an additional motion to dismiss.

September 26, 2007 - The court denied the defendants' motion to dismiss.

November 1, 2006 - The defendants filed a motion to dismiss.

September 29, 2006 - The lead plaintiffs filed a first corrected consolidated complaint. (on behalf of investors who purchased xy common shares between March 3, 2004 and August 9, 2005. The lead plaintiffs allege that the defendants violated the Securities Act of 1933 and the Securities Exchange Act of 1934 by issuing false and misleading statements between March 3, 2004 and August 9, 2005.

April 4, 2006 - The lead plaintiffs and lead counsel were appointed and all cases were consolidated.

October 17, 2005 - Lead plaintiff motions were filed.

September 23, 2005 - An additional investor filed a complaint.

September 19, 2005 - Another investor filed a complaint in the U.S. District Court for the Eastern District of Pennsylvania on behalf of investors who purchased Isolagen Inc (AMEX: ILE) common shares between March 3, 2004 and August 1, 2005.

September 6, 2005 - Another investor filed a complaint in the U.S. District Court for the Southern District of Texas on behalf of investors who purchased Isolagen Inc (AMEX: ILE) common shares between March 3, 2004 and August 1, 2005.

August 17, 2005 - An investor in shares of Isolagen Inc (AMEX: ILE) filed a lawsuit in the U.S. District Court for the Southern District of Texas against Isolagen Inc over alleged violations of Federal Securities Laws in connection with certain allegedly false and misleading statements made between March 3, 2004 and August 1, 2005.

The original complaint charges Isolagen Inc and certain of its officers and directors with violations of the Securities Exchange Act of 1934. Isolagen Inc specializes in the development and commercialization of autologous cellular therapies for soft and hard tissue regeneration (the “Isolagen Process”). Autologous cellular therapy utilizes a process whereby a patient’s own cells are extracted, allowed to multiply and then injected into the patient. In January 2003, defendants began phase I clinical trials aimed at demonstrating the safety and efficacy of using the Isolagen Process to treat dermal defects.

Specifically, the complaint alleges that without solid clinical data developed under controlled conditions, the data gathered in the clinical trials would never meet the FDA’s “adequate and well-controlled” criteria for acceptable clinical trials and Isolagen Inc’s business plan would lack credibility to the investment community. Defendants’ own internal testing showed the Isolagen Process had demonstrated nowhere near the efficacy required to obtain FDA approval, which was needed to make Isolagen Inc profitable. However, between March 3, 2004 and August 1, 2005, defendants touted the efficacy of the Isolagen Process both for dermal and dental treatments, running up Isolagen Inc (AMEX: ILE) stock price to a Class Period high of $12 per share on April 2, 2004.

The complaint further alleges that on or around August 1, 2005, Isolagen Inc disclosed that the preliminary results from its phase III clinical trial of the Isolagen Process for the treatment of contour deformities (wrinkles) had not met all four primary end points and that neither of the two dermal studies had achieved independent statistical significance. On this news, Isolagen Inc (AMEX: ILE) stock price plummeted more than 45%, from $5.50 per share to below $3 per share, on very high volume.